How many stocks does Alphabet Inc. own?

As of Q4 2023, Alphabet Inc. holds 44 positions in their 13F portfolio.

What is Alphabet Inc.'s largest holding?

DXCM at 21.2% of portfolio, worth $456.9M.

What is Alphabet Inc.'s total portfolio value?

$2.2B as of Q4 2023, tracked across 44 holdings.

Is Alphabet Inc. a hedge fund?

Alphabet Inc. is an institutional investment manager required to file SEC 13F reports. This includes hedge funds, mutual funds, pension funds, and other institutions managing over $100M.

How often does Alphabet Inc. report?

13F filings are due quarterly, approximately 45 days after each quarter end.

How has Alphabet Inc.'s portfolio changed in Q4 2023?

View Alphabet Inc.'s latest portfolio changes, new positions, and exits for Q4 2023 on HoldingsIntel.

What is Alphabet Inc.'s investment strategy?

Alphabet Inc. is classified as a Concentrated Value fund based on HoldingsIntel's Fund DNA analysis of 6 behavioral dimensions.

Alphabet Inc.

Institutional investor · Portfolio as of Q4 2023

Q4 2023

SEC 13F snapshot

Top Holdings44 positions

Checking export access…

Activity:

				Price Trend
DXCM DexCom, Inc.	3.7M	$456.9M	21.2%	—	$115.76	+7.20%	18 qtrssince 2019-Q3	Increased 99
CRWD CrowdStrike Holdings, Inc.	1.3M	$327.7M	15.2%	—	$30.67	+108.14%	5 qtrssince 2022-Q4	Unchanged 0
PATH UiPath, Inc.	7M	$174.7M	8.1%	—	$67.93	-63.43%	11 qtrssince 2021-Q2	Decreased 0
VERVDelisted VERVE THERAPEUTICS INC	12.3M	$172.1M	8.0%	—	—	—	11 qtrssince 2021-Q2	Increased 70
GTLB GitLab Inc.	2.6M	$166.7M	7.7%	—	$46.00	+36.86%	7 qtrssince 2022-Q2	Unchanged 0
RVMD Revolution Medicines, Inc.	5.3M	$152M	7.0%	—	$28.68	0.00%	1 qtr	New 95
ARM ADR Arm Holdings plc	2M	$147.3M	6.8%	—	$53.52	+40.41%	2 qtrssince 2023-Q3	Unchanged 0
SNOW Snowflake Inc.	535,604	$106.6M	4.9%	—	$229.13	-13.15%	8 qtrssince 2022-Q1	Unchanged 0
PRME Prime Medicine, Inc.	11.9M	$105.1M	4.9%	—	$18.58	-52.31%	5 qtrssince 2022-Q4	Unchanged 0
FRSH Freshworks Inc.	4M	$94.8M	4.4%	—	$26.26	-10.55%	9 qtrssince 2021-Q4	Unchanged 0
PL Planet Labs PBC	31.9M	$78.9M	3.7%	—	$6.15	-59.84%	9 qtrssince 2021-Q4	Unchanged 0
IVVD Invivyd, Inc.	5.7M	$22.4M	1.0%	—	$42.24	-90.67%	10 qtrssince 2021-Q3	Unchanged 0
RLAY Relay Therapeutics, Inc.	1.6M	$17.3M	0.8%	—	$41.71	-73.60%	14 qtrssince 2020-Q3	Unchanged 0
OSCR Oscar Health, Inc.	1.6M	$14.9M	0.7%	—	$26.88	-65.96%	12 qtrssince 2021-Q1	Decreased 0
RAPTDelisted RAPT THERAPEUTICS INC	540,270	$13.4M	0.6%	—	—	—	17 qtrssince 2019-Q4	Unchanged 0
SANA Sana Biotechnology, Inc.	2.8M	$11.5M	0.5%	—	$33.47	-87.81%	12 qtrssince 2021-Q1	Unchanged 0
LYEL Lyell Immunopharma, Inc.	5.9M	$11.4M	0.5%	—	$324.80	-88.05%	11 qtrssince 2021-Q2	Unchanged 0
BEAM Beam Therapeutics Inc.	321,604	$8.8M	0.4%	—	$18.00	+51.22%	16 qtrssince 2020-Q1	Unchanged 0
DMDelisted Desktop Metal Inc	11M	$8.3M	0.4%	—	—	—	13 qtrssince 2020-Q4	Unchanged 0
GLUE Monte Rosa Therapeutics, Inc.	1.5M	$8.3M	0.4%	—	$22.70	-75.11%	11 qtrssince 2021-Q2	Unchanged 0

$2.2B

AUM

Positions

Q4 2023

Filing

HI rating · 2.5/5

Quarterly 13F Value Change

Reported 13F value ($B)

Reported 13F values and quarter-over-quarter reported value changes; not investment returns.
Quarter	Reported value in US dollars	Reported value change
2022-Q3	$1,958,351,000	6.28834147721%
2022-Q4	$1,721,793,620	-12.0794168155%
2023-Q1	$1,803,455,995	4.74286662765%
2023-Q2	$1,861,041,907	3.1930866159%
2023-Q3	$1,557,004,225	-16.3369605411%
2023-Q4	$2,156,716,052	38.5170327332%

Activity profile

$ moved · Q4'23

New19%Increased52%Decreased16%Exited13%

Composition

Equity vs derivatives

Equity100%Puts0%Calls0%

Holding period

Avg 3.6 quarters

<1Q5%1-4Q9%1-2Y86%2Y+0%

Q4 2023 Summary

Added RVMD and SNCE; exited EQRX, SNCE and EVLO; increased 3, led by DXCM (+3M shares); trimmed 2, led by PATH (−7M shares). Top move: DXCM (INCREASED, conviction 99). Portfolio: $2.2B across 44 positions.

Portfolio Allocation

Top holdings by portfolio weight

DXCM21.18%

CRWD15.20%

PATH8.10%

VERV7.98%

GTLB7.73%

RVMD7.05%

ARM6.83%

SNOW4.94%

PRME4.87%

FRSH4.40%